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EDITORIAL
Renewal of FSP1: A marker of fibrogenesis on human
renal biopsies
Renal biopsy remains the gold standard for the diag-
nosis of renal diseases. Indeed, the prognosis and the
treatment broadly depend on the type of nephropathy
determined on renal biopsy. However, within a given
nephropathy in an individual patient, it may be diffi-
cult to draw up the prognosis from renal biopsy. Reliable
histologic predictors of renal function outcome are still
needed. In this issue of Kidney International, Nishitani
et al present a contributive work to meet this requirement
[1]. Using a “from bench to bedside” approach, the au-
thors performed for the first time on human tissues what
was done in mice 10 years ago, when a fibroblast spe-
cific marker, namely fibroblast-specific protein 1 (FSP1),
was characterized [2]. FSP1 was identified by comparing
murine cDNA libraries obtained from cell cultures of re-
nal tubulointerstitial fibroblasts versus that of proximal
tubular epithelial cells. This new marker of fibroblasts
was not restricted to renal interstitium, but also labeled
fibroblasts in other organs except brain and liver. FSP1
belongs to the S-100 superfamily of small Ca2+-binding
proteins implicated in several cellular and extracellular
functions, including cytoskeletal-membrane interactions,
Ca2+signal transduction, cell growth, differentiation, and
motility, cancer metastasis, and angiogenesis [3]. Further-
more, cDNA encoding FSP1 is similar to mts1 (S100A4)
gene, previously described and implicated in cancer de-
velopment and metastasis [4].
FSP1 and a-smooth muscle actin, two markers
of profibrotic cells
As soon as it was initially described [2], FSP1 was
used to label the cells involved in fibrosis in mouse re-
nal interstitium: therefore, these cells deserved the name
of fibroblasts. FSP1-positive cells coexpressed HSP47,
a chaperone molecule indicative of collagen synthe-
sis, demonstrating that FSP1-positive cells were actu-
ally involved in fibrosis [5]. Whereas scanty interstitial
fibroblasts were found in normal renal interstitium, their
number increased in fibrotic conditions. Although FSP1
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represent a significant progress in our knowledge in fi-
brogenesis, all the questions about renal interstitial cell
types involved in renal fibrosis are not answered. In the
paper by Nishitani et al [1], the dogma of myofibroblast
as the major interstitial cell type responsible for fibrosis
is challenged and the complex heterogeneity of intersti-
tial cell population is underlined. The myofibroblast was
defined as a fibroblast in a reversible activated state in-
volved in scarring and exhibiting contractility for scar re-
traction and strong expression of a-smooth muscle actin
(a-SMA) [6]. In wound healing phenomenon, a-SMA–
positive cells are clearly demonstrated as profibrotic
cells. That latter myofilament protein isoform became
the trademark of activated fibroblasts and their usual
easy marker, allowing fibrosis cellular phenomenons in
many tissues from many species to be studied. It fit well
for interstitial fibroblasts as well as for epithelial cells
engaged in epithelial-mesenchymal transition (EMT).
Nishitani et al [1] suggest the hypothesis that most of a-
SMA–positive cells would originate from vascular cells,
reducing the importance of a-SMA–positive cells orig-
inating from fibroblasts or from epithelial cells trans-
formed by EMT. This opinion should be moderated. First,
Nishitani et al [1] reported that about 10% of interstitial
cells coexpress FSP1 and a-SMA: therefore, a significant
number of interstitial cells are clearly myofibroblasts ex-
pressing the fibroblast specific marker FSP1. Second, in
cell culture experiments under given conditions, tubular
epithelial cells can acquire a-SMA [7]: this EMT phe-
nomenon cannot involve vascular cells because it devel-
ops in a pure epithelial cell population. Finally, one can
wonder what is a fibroblast and what does FSP1 repre-
sent. Fibroblasts are interstitial spindle cells, constantly
but nonspecifically expressing the intermediate filament
vimentin in the cytoskeleton, producing interstitial col-
lagens. In steady state conditions, they are scanty cells
considered as residual resting mesenchymal cells. In fi-
brosis, the number of interstitial collagen-producing cells
is increased and the interstitial cell population is made
of interstitial fibroblasts, most of them resulting from ep-
ithelial cells transformed by EMT, whereas colonization
by circulating bone marrow cells is a minor phenomenon
[5]. FSP1 and/or a-SMA are expressed by these cells. In
this respect, it is difficult to consider FSP1 exclusively as
1366
Editorial 1367
a lineage marker. FSP1 appears more as marker of cells
engaged in fibrogenesis, at least in epithelial cells under-
going EMT, because FSP1 expression precedes complete
EMT [7], transfection of FSP1 induces EMT [2], and in-
activation of FSP1 reduces fibrosis [7].
Pathogenic role of EMT: EMT as a mechanism of tubular
destruction and fibrosis
Since the seminal publication of FSP1 [2], several stud-
ies have taken advantage of this fibroblast marker to ex-
plore renal fibrosis in mouse models. All of these studies
on the development of renal fibrosis pointed out both
types of FSP1-positive cells: interstitial fibroblasts and
tubular epithelial cells, the phenotype of which was trans-
formed into a mesenchymal cell [5, 8]. This change in
phenotype and in cell type is EMT. Besides interstitial
fibrosis, EMT of glomerular epithelial cells has been im-
plicated in glomerulosclerosis [9]. That EMT from tubu-
lar epithelial cells is on par with interstitial fibroblasts is
now definitely established in renal fibrosis. Furthermore,
this phenomenon yields a major component in intersti-
tial cells responsible for fibrosis [5]. EMT is a fascinating
cellular phenomenon emphasizing the plasticity of cells
in renal tissue, where initially during nephrogenesis the
opposite phenomenon is observed. Except for the col-
lecting duct cells, the rest of the nephron results from the
transformation of the metanephric mesenchyme at the
tip of the ureteral bud into epithelial cells, either tubular
or glomerular. EMT in renal fibrosis appears as a rever-
sal of cell transformations associated with nephrogenesis
and generates interstitial cells from destroyed tubules.
EMT is under the control of extracellular milieu and of
growth factors, TGF-b 1, EGF, and FGF2, classically in-
volved in fibrosis, whereas it is inhibited by bone mor-
phogenic protein-7.
Role of glomerular disease in renal fibrosis
A major goal in the Nishitani et al study [1] was to
correlate the renal function decline in IgA nephropa-
thy with interstitial fibrosis as it appears after FSP1 im-
munohistochemistry. Such a study design assumes that
the prognosis of glomerular diseases relies on the tubu-
lointerstitial compartment of the kidney, which is a classic
opinion [10]. Nevertheless, from recent experimental re-
sults, it appears that most of the renal tissue damage is
under the control of glomerular lesions both as starters
and as progression factors of renal tissue fibrosis [11].
Indeed, massive proteinuria from glomerular origin is a
classic downstream mechanism of tubulointerstitial dam-
age. But Kriz and LeHir [11] have recently proposed ad-
ditional mechanisms that seem more active in nephron
loss and development of fibrosis. One consists of mis-
directed filtration at the glomerulotubular junction with
spreading of the filtrate between the tubular epithelium
and the tubular basement membrane, resulting in the
formation of proteinaceous crescents. The second is the
involvement of the origin of the proximal tubule by ob-
structive overgrowth of crescent cells. Both mechanisms
lead to secondary tubular damage, nephron loss, and in-
terstitial fibrosis. Importantly, from serial sections it was
determined that tubule degeneration was localized only
downstream of glomeruli, with crescents obstructing the
origin of proximal tubules, whereas tubules depending
from nonobstructed or normal glomeruli were spared.
This pattern of lesion distribution emphasized the major
role of diseased glomeruli in tubulointerstitial involve-
ment. In Nishitani et al’s paper [1], severe glomerular
lesions with crescents were not described and only mesan-
gial proliferation and sclerosis were scored. That latter
type of glomerular lesion does not fit with the model
of tubulointerstitial fibrosis proposed by Kriz and LeHir
[11].
To shift from experimental to human pathology is the
goal of most research works: the study by Nishitani et al
[1] is a good example of that. Because the spectrum of the
pathophysiology of renal fibrosis in human renal diseases
is wide, many research teams should be interested in test-
ing the useful tool FSP1, unless it remains of confidential
use.
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